Key Details
Price
$2.77Annual Revenue
$9.93 MAnnual EPS
-$24.60Annual ROE
-73.87%Beta
-0.90Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Aug 04, 2022Recent annual earnings:
Feb 17, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Sept 16, 2024Analyst ratings
Recent major analysts updates
Screeners with ISPC included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Woburn, Massachusetts--(Newsfile Corp. - December 20, 2024) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, today announced its strategic initiatives for 2025, expanding services to procure high demand cancer biospecimens, enhancing its ability to support groundbreaking cancer research worldwide. The demand for cancer tissue continues to grow as cancer remains a significant area of focus in medical research and investment.
Woburn, Massachusetts--(Newsfile Corp. - December 13, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today positive results attributed to its Next Day Quote Program ("NDQ"). This next-day quote service for researchers and providers is tailored to accelerate the biospecimen transaction process and delivers accurate biospecimen sample pricing within 24 hours of receiving the customer request.
Woburn, Massachusetts--(Newsfile Corp. - December 12, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it has appointed Robert Lim as CEO and director. Mr. Lim is the principal and co-founder of De Novo Law Corporation, a Vancouver-based law firm specializing in corporate/commercial law and civil litigation.
Biospecimen Market To Exceed $13.5 Billion USD By 2032 Woburn, Massachusetts--(Newsfile Corp. - November 8, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the addressable Biospecimen contract research services market is attractive and growing. In fact, according to AceInsight Analytic, the market is presently valued at USD 4.4 billion as of 2023 and is predicted to reach USD 13.5 billion by the year 2032, growing at a 13.3% CAGR during the forecast period.
WOBURN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today a significant enhancement to its searchable inventory that provides researchers with increased access to a wide array of biospecimens vital to advancing oncology research and treatments.
WOBURN, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it will effect a reverse stock split of its issued and outstanding shares of common stock, par value $0.0001 per share, as well as any shares of common stock held by the Company in treasury, at a ratio of 1-for-20. The reverse stock split will become effective at 4:30 p.m. Eastern Time on September 13, 2024, and the Company's common stock will begin trading on a split-adjusted basis when the market opens on September 16, 2024. The Company's common stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol "ISPC." The new CUSIP number for the Company's common stock following the reverse stock split will be 45032V207.
iSpecimen Inc. (NASDAQ:ISPC ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Phil Carlson - IR, KCSA Strategic Communications Tracy Curley - CEO and CFO Leslie Hoyt - VP, Operations Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Operator Good morning everyone and welcome to the iSpecimen Second Quarter 2024 Earnings Conference Call. At this time, participants are in a listen-only mode.
Revenue increased 76% year-over-year to approximately $2.86 million Brielan Smiechowski Named SVP of Sales and Business Development LEXINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three and six month periods ended June 30, 2024.
iSpecimen Inc. (NASDAQ: ISPC) Q1 2024 Earnings Conference Call on May 7, 2024 at 8:30 AM ET with company representatives including Phil Carlson, Tracy Curley, and Leslie Hoyt. Conference call participants include Matt Hewitt from Craig Hallum Capital. The call is being recorded.
The Company will now report results after the market closes on March 13, 2024 and reschedules conference call to Thursday, March 14, 2024 at 8:30am Eastern The Company will now report results after the market closes on March 13, 2024 and reschedules conference call to Thursday, March 14, 2024 at 8:30am Eastern
FAQ
- What is the primary business of iSpecimen?
- What is the ticker symbol for iSpecimen?
- Does iSpecimen pay dividends?
- What sector is iSpecimen in?
- What industry is iSpecimen in?
- What country is iSpecimen based in?
- When did iSpecimen go public?
- Is iSpecimen in the S&P 500?
- Is iSpecimen in the NASDAQ 100?
- Is iSpecimen in the Dow Jones?
- When was iSpecimen's last earnings report?
- When does iSpecimen report earnings?
- Should I buy iSpecimen stock now?